- Leclerc hails Ferrari fightback from torrid Singapore GP qualifying
- Belgian Evenepoel retains world title in 'toughest time trial'
- Sosa rescues point for Forest against Brighton
- Last-gasp Boniface gives Leverkusen victory over Wolfsburg in seven-goal thriller
- Swiss voters reject environment, pensions reforms: official results
- No fairytale ending for Ricciardo after 13 years in Formula One
- Israel and Hezbollah urged to step back from the brink
- What is the UN's 'Pact for the Future'?
- Norris dominates Singapore Grand Prix to cut Verstappen's title lead
- From bullets to ballots: Sri Lanka's comrade president-elect
- McLaren's Lando Norris wins Singapore GP to narrow F1 title race
- UN adopts pact promising to build 'brighter future' for humanity
- Military escalation not in Israel's 'best interest': White House
- Marxist leader declared Sri Lanka's president-elect
- Classes resume at Bangladesh university at heart of protests
- 'Barely anyone left': Sudan's El-Fasher devastated by fighting
- 'Warrior' Joshua vows to fight on despite Dubois mauling
- Martin extends MotoGP lead as Bastianini wins at Misano and Bagnaia crashes out
- New French government instantly under pressure on multiple fronts
- Australia's Brown adds world title to Olympic time trial gold
- Russian strike on Ukraine's Kharkiv wounds 21
- UK's Starmer rules out austerity as Labour conference opens
- Swiss voters reject environment, pensions reforms: projected results
- Israel says 'landed blows' on Hezbollah as Lebanon violence intensifies
- Roma CEO steps down amid anger over club icon De Rossi's sacking
- Incoming French government under pressure on multiple fronts
- Hezbollah rockets strike near Israel's Haifa as UN warns of 'catastrophe'
- Haddad Maia roars back to beat Kasatkina in Korea Open final
- All-rounder Ashwin powers India to 280-run Test win over Bangladesh
- Failed Springbok 'gamble' sets up rugby championship decider
- Lebanon strikes send Israelis to shelters as UN warns of 'catastrophe'
- Far-right AfD eyes new win in east German state vote
- Tony Popovic set to become new Socceroos coach - reports
- All-round Ashwin powers India to big Test win over Bangladesh
- NZ chase 275 to win first Sri Lanka Test after Patel bags six
- Ashwin bags six wickets as India hammer Bangladesh in first Test
- Nascent French government under pressure on multiple fronts
- Angry French cognac makers see red over Chinese tariffs threat
- Protect the prosciutto: Italy battles swine fever
- UN holds 'Summit of the Future' to tackle global crises
- Marxist leader set to become Sri Lanka's next president
- From blades to pull-up bars: UK charity tackles knife crime
- Swiss vote on pensions and environment protections
- No pain, no gain: Chinese pro wrestlers fight for recognition
- UAE leader seeks to deepen 'strategic' ties in US visit during Mideast crisis
- Hezbollah takes heavy hits but still fighting Israel
- Floods, landslides hit central Japan months after major quake
- All Blacks coach Robertson demands better finishing
- Argentina edge South Africa to keep title hopes alive
- Biden says China 'testing us,' in hot mic remarks to Quad allies
US approves first vaccine against chikungunya virus: drug regulator
US health authorities on Thursday approved the world's first vaccine for chikungunya, a virus spread by infected mosquitoes that the Food and Drug Administration called "an emerging global health threat."
The vaccine, developed by Europe's Valneva which will be marketed under the name Ixchiq, was approved for people 18 and over who are at increased risk of exposure, the FDA said.
Ixchiq's green-light by the US drug regulator is expected to speed the vaccine's rollout in countries where the virus is most prevalent.
Chikungunya, which causes fever and severe joint pain, is most prevalent in tropical and subtropical regions of Africa, southeast Asia and part of the Americas.
"However, chikungunya virus has spread to new geographical areas causing a rise in global prevalence of the disease," the FDA said, reporting more than 5 million cases in the past 15 years.
"Infection with chikungunya virus can lead to severe disease and prolonged health problems, particularly for older adults and individuals with underlying medical conditions," senior FDA official Peter Marks said in a statement.
"Today's approval addresses an unmet medical need and is an important advancement in the prevention of a potentially debilitating disease with limited treatment options."
The vaccine is injected in one dose and contains a live, weakened version of the chikungunya virus, as is standard with other vaccines.
Two clinical trials were carried out in North America on 3,500 people. Headache, fatigue, muscle and joint pain, fever and nausea were commonly reported side effects.
Serious reactions were reported in 1.6 percent of Ixchiq recipients in the trials, with two requiring hospitalization.
D.Cunningha--AMWN